Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1996 2
1999 1
2000 1
2002 1
2003 1
2008 1
2012 1
2013 1
2014 1
2015 3
2016 2
2017 1
2018 1
2019 1
2020 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean e natour[Author] (46 results)?
Resident memory T cells, critical components in tumor immunology.
Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, Tihy I, Tartour E. Mami-Chouaib F, et al. Among authors: tartour e. J Immunother Cancer. 2018 Sep 4;6(1):87. doi: 10.1186/s40425-018-0399-6. J Immunother Cancer. 2018. PMID: 30180905 Free PMC article. Review.
CD103 binds to the epithelial cell marker E-cadherin, thereby favoring the location and retention of T(RM) in epithelial tumor regions in close contact with malignant cells. The CD103-E-cadherin interaction is required for polarized exocytosis of lytic granules, in …
CD103 binds to the epithelial cell marker E-cadherin, thereby favoring the location and retention of T(RM) in epithelial tumor region …
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.
Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L. Daillère R, et al. Among authors: tartour e. Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4. Immunity. 2016. PMID: 27717798 Free article.
The immune sensor, NOD2, limited CTX-induced cancer immunosurveillance and the bioactivity of these microbes. Finally, E. hirae and B. intestinihominis specific-memory Th1 cell immune responses selectively predicted longer progression-free survival in advanced lung and ova …
The immune sensor, NOD2, limited CTX-induced cancer immunosurveillance and the bioactivity of these microbes. Finally, E. hirae and B …
Trial Watch: Peptide-based anticancer vaccines.
Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Among authors: tartour e. Oncoimmunology. 2015 Jan 9;4(4):e974411. doi: 10.4161/2162402X.2014.974411. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137405 Free PMC article. Review.
Currently, both experimentalists and clinicians are focusing their efforts on the identification of so-called tumor rejection antigens, i.e., TAAs that can elicit an immune response leading to disease eradication, as well as to combinatorial immunostimulatory interventions …
Currently, both experimentalists and clinicians are focusing their efforts on the identification of so-called tumor rejection antigens, i. …
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Among authors: tartour e. Oncoimmunology. 2015 Mar 2;4(4):e1008866. doi: 10.1080/2162402X.2015.1008866. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137404 Free PMC article. Review.
These include various chemotherapeutics routinely employed in the clinic (e.g., doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin) as well as some anticancer agents that are still under preclinical or clinical develo …
These include various chemotherapeutics routinely employed in the clinic (e.g., doxorubicin, epirubicin, idarubicin, mitoxantrone, bl …
Sunitinib in kidney cancer: 10 years of experience and development.
Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S. Nassif E, et al. Among authors: tartour e. Expert Rev Anticancer Ther. 2017 Feb;17(2):129-142. doi: 10.1080/14737140.2017.1272415. Epub 2016 Dec 27. Expert Rev Anticancer Ther. 2017. PMID: 27967249 Review.
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Combe P, et al. Among authors: tartour e. Oncoimmunology. 2015 Mar 19;4(5):e1001236. doi: 10.1080/2162402X.2014.1001236. eCollection 2015 May. Oncoimmunology. 2015. PMID: 26155388 Free PMC article. Review.
All vaccine trials have failed to meet their endpoints although they have highlighted potential predictive biomarkers (e.g., pre-existing immune response, hematological parameters, tumor burden). ...Phase III trials are focusing on the possible synergy between therapeutic …
All vaccine trials have failed to meet their endpoints although they have highlighted potential predictive biomarkers (e.g., pre-exis …
Trial watch: IDO inhibitors in cancer therapy.
Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Among authors: tartour e. Oncoimmunology. 2014 Dec 15;3(10):e957994. doi: 10.4161/21624011.2014.957994. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941578 Free PMC article. Review.
Indoleamine 2,3-dioxigenase 1 (IDO1) is the main enzyme that catalyzes the first, rate-limiting step of the so-called "kynurenine pathway", i.e., the metabolic cascade that converts the essential amino acid L-tryptophan (Trp) into L-kynurenine (Kyn). ...
Indoleamine 2,3-dioxigenase 1 (IDO1) is the main enzyme that catalyzes the first, rate-limiting step of the so-called "kynurenine pathway", …
Control of tumor development by intratumoral cytokines.
Pages F, Vives V, Sautès-Fridman C, Fossiez F, Berger A, Cugnenc PH, Tartour E, Fridman WH. Pages F, et al. Among authors: tartour e. Immunol Lett. 1999 May 3;68(1):135-9. doi: 10.1016/s0165-2478(99)00042-5. Immunol Lett. 1999. PMID: 10397168 Review.
The production of IL17 and IL18, inducers of IL6 and IFNbeta respectively is regulated in these tumors and may control the levels of the effector cytokines, i.e. IL6 and IFNbeta. The mechanisms by which these cytokines act are linked to the recruitment of effector cells su …
The production of IL17 and IL18, inducers of IL6 and IFNbeta respectively is regulated in these tumors and may control the levels of the eff …
Prognostic Significance of the Microenvironment in Human Papillomavirus Oropharyngeal Carcinoma: A Systematic Review.
Baudouin R, Hans S, Lisan Q, Morin B, Adimi Y, Martin J, Lechien JR, Tartour E, Badoual C. Baudouin R, et al. Among authors: tartour e. Laryngoscope. 2024 Apr;134(4):1507-1516. doi: 10.1002/lary.31010. Epub 2023 Aug 29. Laryngoscope. 2024. PMID: 37642393 Review.
The PEO (Population, Exposure, and Outcome) framework is detailed as follows: P: patients with oropharyngeal squamous cell carcinomas, E: human papillomavirus (HPV), and O: histological and immunological composition of the tumoral microenvironment (TME). ...
The PEO (Population, Exposure, and Outcome) framework is detailed as follows: P: patients with oropharyngeal squamous cell carcinomas, E …
22 results